Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | ||
| Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | ||
| Camzyos | mavacamten | Obstructive hypertrophic cardiomyopathy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | ||
| Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
| Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete |
Last Updated : May 10, 2024